Population pharmacokinetics of mobocertinib in healthy volunteers and patients with non–small cell lung cancer

N Gupta, PB Pierrillas, MJ Hanley… - CPT …, 2022 - Wiley Online Library
… Neeraj Gupta is employed by Takeda; Philippe B. Pierrillas is employed by Certara and is a
consultant for Takeda; Michael J. Hanley is employed by Takeda; Steven Zhang is employed …

[HTML][HTML] Model-based adaptive optimal design (MBAOD) improves combination dose finding designs: an example in oncology

PB Pierrillas, S Fouliard, M Chenel, AC Hooker… - The AAPS journal, 2018 - Springer
Abstract Design of phase 1 combination therapy trials is complex compared to single therapy
trials. In this work, model-based adaptive optimal design (MBAOD) was exemplified and …

Comparison of the static in vivo approach to a physiologically based pharmacokinetic approach for metabolic drug–drug interactions prediction

M Tod, PB Pierrillas, L Bourguignon… - International journal of …, 2016 - Future Science
Background: The in vivo mechanistic static model (IMSM) and the physiologically based
pharmacokinetic (PBPK) model are two approaches used to predict the magnitude of drug–drug …

Prediction of human nonlinear pharmacokinetics of a new Bcl-2 inhibitor using PBPK modeling and interspecies extrapolation strategy

PB Pierrillas, E Henin, K Ball, J Ogier, M Amiel… - Drug Metabolism and …, 2019 - ASPET
S 55746 ((S)-N-(4-hydroxyphenyl)-3-(6-(3-(morpholinomethyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)benzo[d][1,3]dioxol-5-yl)-N-phenyl-5,6,7,8-tetrahydroindolizine-1-carboxamide) …

[HTML][HTML] Improvement of parameter estimations in tumor growth inhibition models on xenografted animals: a novel method to handle the interval censoring caused by …

PB Pierrillas, M Tod, M Amiel, M Chenel, E Henin - The AAPS journal, 2016 - Springer
The purpose of this study was to explore the interval censoring induced by caliper measurements
on smaller tumors during tumor growth experiments in preclinical studies and to show …

Improvement of parameter estimations in tumor growth inhibition models on xenografted animals: handling sacrifice censoring and error caused by experimental …

PB Pierrillas, M Tod, M Amiel, M Chenel, E Henin - The AAPS journal, 2016 - Springer
The purpose of this study was to explore the impact of censoring due to animal sacrifice on
parameter estimates and tumor volume calculated from two diameters in larger tumors during …

Tumor growth inhibition modelling based on receptor occupancy and biomarker activity of a new Bcl-2 inhibitor in mice

PB Pierrillas, E Henin, J Ogier, L Kraus-Berthier… - … of Pharmacology and …, 2018 - ASPET
The Bcl-2 inhibitor S 55746 ((S)-N-(4-hydroxyphenyl)-3-(6-(3-(morpholinomethyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)benzo[d][1,3]dioxol-5-yl)-N-phenyl-5,6,7,8-…

Translational approach from preclinical to clinical: comparison of dose finding methods of a new Bcl2 inhibitor using PK-PD modeling and interspecies extrapolation

PB Pierrillas, E Henin, J Ogier, M Amiel… - Investigational New …, 2020 - Springer
The attrition rate of anticancer drugs during the clinical development remains very high.
Interspecies extrapolation of anticancer drug pharmacodynamics (PD) could help to bridge the …

[PDF][PDF] Evaluation of DDI-predictor for prediction of the impact of CYP polymorphism on drug exposure.

M Tod, PB Pierrillas, L Bourguigon, S Goutelle - ddi-predictor.org
• Quantitative prediction of the impact of cytochrome (CYP) polymorphism on drug exposure
is useful to identify the pharmacogenetic studies to be performed during clinical drug …

Population PK and semimechanistic PK/PD modeling and simulation of relugolix effects on testosterone suppression in men with prostate cancer

TY Lee, PB Pierrillas, YW Lin… - Clinical …, 2023 - Wiley Online Library
Relugolix, the first orally active, nonpeptide gonadotropin‐releasing hormone receptor
antagonist, is approved in the United States and the European Union for the treatment of adult …